Brooks Laboratories Limited Stock Price Today (NSE: BROOKS)

Brooks Laboratories Limited

61.022.07 (3.28%)
Market Closed

Fundamental Score

...

Brooks Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Brooks Laboratories Limited share price today is 61.02, down 3.28% on NSE/BSE as of 16 September 2026. Brooks Laboratories Limited (BROOKS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 179.75 (Cr). The 52-week high for BROOKS share price is 160.00 and the 52-week low is 36.30. At a P/E ratio of 13.59x, BROOKS is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 22.24% and a debt-to-equity ratio of 0.06.

Brooks Laboratories Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
71.40
Low
58.50
Volume
25.9K
Change
+5.16%

Brooks Laboratories Limited share price chart: 5.16% return over the past month. 52-week high ₹160.00, 52-week low ₹36.30.

Brooks Laboratories Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
64.4964.7059.1361.0251.52K (Cr)
67.7067.7062.8063.0926.35K (Cr)
64.7069.7263.1265.691.02L (Cr)
66.0066.0063.1063.8524.31K (Cr)
64.6165.5061.1562.9917.28K (Cr)
69.7069.7561.5263.3064.34K (Cr)
66.7070.8066.6067.7025.78K (Cr)
65.9566.6864.0066.0712.92K (Cr)
65.1565.9564.0064.1524.89K (Cr)
66.0066.1064.0065.1023.54K (Cr)

Brooks Laboratories Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
67.9570.8059.1361.02-10.20%
61.1671.4058.5066.54+8.80%
68.8679.6957.5060.98-11.44%
68.5579.0061.6168.86+0.45%
56.1565.2944.5665.29+16.28%
38.9879.7038.9855.98+43.61%
63.5065.8836.3037.11-41.56%
61.9882.4458.3567.11+8.28%
80.5080.5861.3261.55-23.54%
103.99105.6568.1180.14-22.93%
113.25113.6995.25102.20-9.76%
134.25138.34104.51110.93-17.37%

Returns & Performance

Excellent

Return on Equity (ROE)

22.24%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

5.85%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

-13.87%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Brooks Laboratories Limited Valuation Check

Excellent

Price to Earnings (P/E)

13.59x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

52.62%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Good

DII Holding

10.38%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-118.64%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-10.00%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

2.11%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

5.76%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

26.75%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.06x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

7.95x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-78.47 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Brooks Laboratories Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of BROOKS across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Strong Return on Equity (22.24%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Attractive Valuation (P/E: 13.59 vs Industry: 34.89)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Strong Profit Growth Track Record (26.75% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.06)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (7.95x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (52.62%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

7 factors identified

Suboptimal ROCE (5.85%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (-13.87%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Profit Decline Concern (-118.64%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Revenue Contraction (-10.00%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Limited Growth History (2.11% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Negative Free Cash Flow (₹-78.47 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Brooks Laboratories Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Brooks Laboratories Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
58.9/100
61
₹179.75
13.6
Average
22.24%
Excellent
5.85%
Poor
0.1
Excellent
26.75%
Excellent
2.11%
Average
0.00%
66.4/100
1865
₹447445.46
37.0
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9488
₹251432.00
86.1
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4930
₹166860.78
78.8
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1127
₹112514.52
25.1
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1363
₹110118.03
32.7
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1937
₹104646.43
95.6
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1699
₹97754.71
26.5
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2100
₹96022.50
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1145
₹95607.50
29.6
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2265
₹93544.50
45.8
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Brooks Laboratories Limited Quarterly Performance

Latest quarterly metrics for BROOKS — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-10.00%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-118.64%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

2.11%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

26.75%

Compounded annual net profit growth over 5 years

Brooks Laboratories Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for BROOKS — calculated from daily price history

56RSI 14
Neutral — RSI 56

Momentum is balanced — neither overbought nor oversold.

SMA 50
65
▼ Price below SMA 50 — Short-term bearish
SMA 200
69
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
24K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Brooks Laboratories Limited Financial Statements

Annual income statement, balance sheet and cash flow for Brooks Laboratories Limited (BROOKS) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Brooks Laboratories Limited

Loading latest quarterly results...

About BROOKS (Brooks Laboratories Limited)

Brooks Laboratories Ltd is a dynamic pharmaceutical manufacturer carving a niche for itself in the complex world of drug development and production. They operate as a comprehensive... service provider, collaborating with pharmaceutical companies across India and global markets. Brooks Labs offers a unique blend of innovative solutions and rigorous quality control, functioning as a trusted partner throughout the drug lifecycle. From the initial stages of formulation and analytical development to large-scale commercial manufacturing, the company demonstrates a commitment to precision and efficiency. They aim to empower their partners to bring innovative medications to the market, ensuring accessibility and improved patient outcomes through reliable and cost-effective production processes. The core of Brooks Laboratories' capabilities lies in its diversified manufacturing platform, designed to handle a wide spectrum of pharmaceutical dosage forms. This encompasses advanced sterile injectables, including both liquid and lyophilized formats, crucial for delivering critical medications directly into the bloodstream. Beyond injectables, they also specialize in the production of diverse solid oral dosage forms. These include conventional tablets and specialized dry powder syrups, catered to patient populations of all ages. Furthermore, Brooks Labs maintains dedicated facilities for manufacturing specialized products like ophthalmic and nasal solutions, demonstrating their versatility and commitment to meeting varied therapeutic needs. With this wide-ranging production capacity, Brooks Laboratories positions itself as a versatile manufacturing solution for pharmaceutical innovators. Focusing on critical therapeutic areas, Brooks Laboratories offers robust manufacturing capabilities in high-demand segments like anti-infectives, pain management, and oncology. Their expertise in handling potent and cytotoxic substances allows them to produce complex formulations with precision and safety. These products are often essential treatments for serious illnesses and chronic conditions. Through rigorous adherence to international quality standards and dedicated facilities, Brooks Laboratories ensures the integrity and efficacy of every product they manufacture. This commitment to excellence allows the company to contribute significantly to the global healthcare ecosystem, providing access to life-saving medications and improved quality of life for patients worldwide.

Company Details

Symbol:BROOKS
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Prashant Rathi
Chief Financial Officer
Ms. Krutika Mohan Rane
Company Secretary & Compliance Officer
Dr. Durga Shankar Maity M.Sc.
Whole Time Director

BROOKS Share Price: Frequently Asked Questions

What is the current share price of Brooks Laboratories Limited?

Brooks Laboratories Limited (BROOKS) trades at ₹61.02 on NSE and BSE. Market cap ₹179.75 (Cr). Educational data only.

What is the P/E ratio of Brooks Laboratories Limited?

Brooks Laboratories Limited has a P/E of 13.59x vs industry average 34.89x.

What is the Bull Run score for Brooks Laboratories Limited?

Brooks Laboratories Limited has a Bull Run score of 58.9/100 based on 25+ financial parameters.

Does Brooks Laboratories Limited pay dividends?

Brooks Laboratories Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Brooks Laboratories Limited?

Brooks Laboratories Limited has ROE of 22.24%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Brooks Laboratories Limited?

Brooks Laboratories Limited has debt-to-equity of 0.06.

Is Brooks Laboratories Limited a good investment?

Bull Run gives Brooks Laboratories Limited a score of 58.9/100. This is not investment advice — consult a SEBI-registered advisor.